Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5629195 | 0.86 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL17085330 | 0.83 | PKM (0.68) | ALDH1A1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL31570077 | 0.83 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL202986 | 0.82 | PKM (0.48) | ALDH1A1SMN1; SMN2KMT2AMEN1MAPT | |
| SCHEMBL6160631 | 0.80 | MAPT (0.72) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL11448823 | 0.80 | MAPT (0.68) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL17434413 | 0.80 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL2911660 | 0.79 | KMT2A (0.54) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL7968011 | 0.78 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL6162009 | 0.78 | PKM (0.53) | ALDH1A1SMN1; SMN2LMNAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | ALDH1A1 4635/4885SMN1; SMN2 3724/4885KMT2A 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.